“The Spectrum article caused us to ask ourselves: Did we miss something?” he says. When seeking a PA for a Tier 2 or NP antipsychotic, remember that it could take up to 1 business day after all requested information is received before a decision is rendered.Aripiprazole, a commonly used antipsychotic medication marketed as Abilify, curtails aggressive behavior in autistic children, according to a new review, but not enough is known about the drug’s side effects or its efficacy in different populations.Ī feature in Spectrum last year prompted the new review, says Alan Poling, lead investigator and professor of psychology at Western Michigan University in Kalamazoo. Clinical criteria have been established which must be met before a Tier 2 & Non-Preferred (Tier 2 & NP) antipsychotic is approved (see Clinical Criteria). As always, a PREFERRED antipsychotic (see Preferred Drug List) does not require a prior authorization, if prescribed within the FDA Guidelines for the dose and frequency. To meet this goal, the program has established a prior authorization (PA) process. The goal of the program is to have prescribers, whenever appropriate, prescribe antipsychotics using FDA guidelines for diagnosis, dose and frequency in the most cost-effective manner. It was designed to address a variety of concerns, including the off-label use of antipsychotics. This program was launched in September 2012. Tier 2 & Non-Preferred Antipsychotic Review Program #134 – Expansion of Peer Review Program ages 0 to 17 #122 – No PA Required for Abilify for ages 10 - 17 #115 – PRP expands to include youth up to age 10 years #198 – PRP expands to include 10 to 17 year olds The program works in partnership with the Mental Hygiene Administration (MHA) and the University of Maryland (UMD) School of Pharmacy and Division of Child and Adolescent Psychiatry. OPS and MHA hosted a webinar to discuss the PRP and answer questions regarding this program on September 15, 2011. In January 2014, the program expanded to include any Medicaid recipient 17 years or younger who is prescribed any antipsychotic. In July 2012, it expanded to encompass children under 10 years of age. This program began in October 2011 and initially addressed the use of antipsychotics in Medicaid patients under five years of age. The goal of the program is to ensure that children and adolescents receive optimal treatment in conjunction with appropriate non-pharmacologic measures in the safest manner possible. This program was established to address concerns that an increasing number of children are being prescribed antipsychotics and there is a lack of laboratory monitoring of those children. Tier 2 & Non-Preferred Antipsychotic Review Program.To support providers who prescribe this drug class, the Office of Pharmacy Services (OPS) has established two programs. Published guidelines addressing some of the above issues include, but are not limited to, the American Academy of Child and Adolescent Psychiatry Practice Parameters for Atypical Antipsychotics and The American Diabetes Association/American Psychiatric Association consensus statement issued in 2004 recommending monitoring body mass index and blood glucose and blood lipid levels on patients taking atypical antipsychotics. In the public and health care arena concerns have been raised, not only about the “off-label" prescribing, but also about the lack of side effect (including weight, body mass index and blood glucose and lipid levels) monitoring of antipsychotics.įederally, a Government Accountability Office (GAO) report has outlined concerns about antipsychotic use in Medicaid recipients in Foster Care. However, there are situations in which a clinician may prescribe an antipsychotic “off-label". Antipsychotics are FDA approved for a variety of diagnoses including but not limited to: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression (as adjunct treatment) and Autistic Disorder (to treat associated irritability).
0 kommentar(er)
